Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDAAA Impact Analysis: Year One

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

If you want to market a new pharmaceutical or vaccine ingredient in the U.S., you should consult a copy of the 2007 Food & Drug Administration Amendments Act

You may also be interested in...

The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two

FDA has invoked formal Risk Evaluation & Mitigation Strategy Authority almost as often the last five months as it did in the first full year of the program. Use of more intense REMS-those with communication plans and elements to assure safe use-is increasing even faster, and indications are this is the leading edge of a wave of new restrictive programs. REMS unquestionably delay approvals, FDA officials acknowledge-and yet, more drugs are coming out of FDA.

Waking Up to REMS (Part 1): Don't Believe the Lack of Hype

FDA's top management can't be accused of overstating the importance of the agency's new drug safety tools. But sponsors need to wake up to the reality: the REMS are a critical fact of drug development and marketing.

Is The Opioid REMS Too Big To Study?

US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts